MedTrace Logo

Clinical Study of Compound Ciwujia Granules in the Treatment of Depression

NCT07085143 · Status: ACTIVE_NOT_RECRUITING · Phase: PHASE4 · Type: INTERVENTIONAL · Enrollment: 60

Last updated 2026-04-23

No results posted yet for this study

Summary

The purpose of this clinical trial is to evaluate the therapeutic efficacy and safety of Compound Ciwujia Granules in treating depression disorder (heart-spleen deficiency syndrome). The study primarily aims to address the following key questions:

* Can Compound Ciwujia Granules effectively alleviate depressive symptoms in patients with heart-spleen deficiency syndrome?
* What adverse reactions might participants experience while taking Compound Ciwujia Granules? Researchers will compare Compound Ciwujia Granules to a placebo (a look-alike substance that contains no drug) to see if Compound Ciwujia Granules works to treat depression disorder.

Participants are required to complete the following procedures:

1. Take Compound Ciwujia Granules or placebo twice daily for 8 weeks;
2. Continue concomitant SSRIs throughout the treatment period;
3. Return to the hospital for scheduled assessments at Week 4 and Week 8.

Conditions

  • Depression - Major Depressive Disorder
  • Depression Disorders

Interventions

DRUG

Compound Ciwujia Granules

Take Compound Ciwujia Granules or placebo twice daily for 8 weeks; Continue concomitant SSRI medication therapy throughout the treatment period;

DRUG

placebo

1. Take placebo twice daily for 8 weeks; 2. Continue concomitant SSRI medication therapy throughout the treatment period;

Sponsors & Collaborators

  • Heilongjiang Quanle Pharmaceutical Co., Ltd.

    collaborator INDUSTRY

  • Shanghai Mental Health Center

    lead OTHER

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
QUADRUPLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Max Age
65 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2025-10-01
Primary Completion
2026-06-20
Completion
2026-07-30

Countries

  • China

Study Locations

More Related Trials

Entities

Drugs

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT07085143 on ClinicalTrials.gov